International Journal of Radiation Research

en The Aurora-A/NPAT/Wnt-β-catenin pathway enhances the metastasis and stemness of lung cancer cells Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;">Background: Aurora-A kinase (Aurora-A) serves as an oncogene in many cancers, but whether its expression is linked to the stemness of lung cancer (LC) cells remains obscure. Hence, this study probed the impact as well as mechanism of Aurora-A in affecting the stemness of LC cells. Materials and Methods: Functional assays were implemented to assess the malignant behaviors along with stemness of LC cells. Western blot analysis detected the stemness markers together with the Wnt-β-catenin pathway-linked genes protein levels. TOP/FOP-Flash reporter assay assessed the activity of the Wnt/β-catenin pathway. Hematoxylin and eosin staining as well as immunohistochemistry analysis of tumor tissues were implemented. Results: Our findings indicated that Aurora-A was up-regulated in LC cells, and silenced Aurora-A hindered LC cell proliferation, migration, invasion along with stemness. Nuclear protein, coactivator of histone transcription (NPAT) was also high-expressed in LC cells, and was positively modulated by Aurora-A. Silenced NPAT inhibited LC cell malignant behaviors along with stemness. Aurora-A activated the Wnt/β-catenin pathway and promoted LC cell malignant behaviors along with stemness via regulating NPAT. In an established xenograft model, Aurora-A inhibition reduced tumor growth, metastasis along with stemness in vivo. Conclusion: In summary, Aurora-A/NPAT/Wnt-β-catenin signaling pathway accelerates LC cell malignant behaviors along with stemness. The modulation of Aurora-A might be an underlying therapeutic approach in LC patients.</div> lung cancer, malignant, Aurora-A, NPAT, Wnt-β-catenin. 147 154 http://ijrr.com/browse.php?a_code=A-10-1-1304&slc_lang=en&sid=1 Y. Zhao zhaoyan_nsyy@163.com 7900319475328460029573 7900319475328460029573 Yes Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong 518052, China Y. Zhao 7900319475328460029574 7900319475328460029574 No Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong 518052, China P. Li 7900319475328460029575 7900319475328460029575 No Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong 518052, China X. Fu 7900319475328460029576 7900319475328460029576 No Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong 518052, China J. Duan 7900319475328460029577 7900319475328460029577 No Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong 518052, China Y. Tang 7900319475328460029578 7900319475328460029578 No Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong 518052, China Y. Ma 7900319475328460029579 7900319475328460029579 No Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong 518052, China Q. Zhou zqm961221@163.com 7900319475328460029580 7900319475328460029580 No Department of Medical Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong 518052, China